NCT07237282 is a Phase 1 clinical trial of AVIHepC1 in Hepatitis C, sponsored by University of Alberta.

Who is sponsoring NCT07237282?

NCT07237282 is sponsored by University of Alberta.

What drugs are being tested in NCT07237282?

Interventions in NCT07237282: AVIHepC1, Normal Saline.

What condition does NCT07237282 study?

NCT07237282 studies Hepatitis C.

Is NCT07237282 still recruiting?

NCT07237282 is currently not yet recruiting. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT07237282

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

Not yet recruiting Phase 1 Last updated 6 February 2026

What this trial tests

Phase 1 trial testing AVIHepC1 in Hepatitis C in 27 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
1 January 2027

1 July 2027

Quick facts

Lead sponsor	University of Alberta
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	27
Start date	1 March 2026
Primary completion	1 January 2027
Estimated completion	1 July 2027
Sites	3 locations across Canada

Drugs / interventions tested

AVIHepC1 — full drug profile →
Normal Saline

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

University of Alberta

Who can join

Adults 18 to 45, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the safety and antibody (germ fighters) response of the experimental (investigational) vaccine against HCV when injected into the arm of healthy adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07237282 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07237282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing